The HEROES study evaluated RPC4046 in adults with active eosinophilic esophagitis (EoE). In this exploratory substudy, we investigated whether RPC4046 modulates epithelial-mesenchymal transition (EMT). METHODS: Esophageal biopsy sections were taken at baseline and week 16 from 69 patients receiving weekly subcutaneous RPC4046 360 mg (n526), 180 mg (n519), or placebo (n524). Slides were stained by duplex immunofluorescence for e-cadherin and vimentin, counterstained nuclei with DAPI, and scanned at 20x via multispectral digital microscopy. A machine-learning algorithm mapped each slide's epithelial compartment. Nuclear, cytoplasmic, and membrane areas of each epithelial cell were defined and fluorescence intensity of each marker on a per-cell basis was recorded. Endpoints included change from baseline in percentage of vimentin-positive epithelial cells, change in total e-cadherin expression/ cell, and change in vimentin:e-cadherin ratio/cell. RESULTS: Change from baseline in mean percentage of vimentinpositive cells was 24.24%, 22.75%, and 20.94% for RPC4046 360 mg, 180 mg, and placebo, respectively (P<0.05, 360 mg vs placebo). Change in mean e-cadherin expression per cell was 101.6, 102.4, and 18.3, respectively (P<0.05, each dose group vs placebo). Change in vimentin:e-cadherin ratio was significantly different from zero for 360 mg (20.30) and 180 mg (20.18) (P<0.05). Similar effects for all markers were observed in each esophageal sampled region. CONCLUSIONS: RPC4046 significantly improved esophageal tissue EMT markers in patients with EoE, with a greater effect observed with 360 mg. Results support the hypothesis that prevention of IL-13 binding to receptor subtypes IL-13Ra1 and IL-13Ra2 favorably impacts inflammatory and remodeling pathways and may reduce development of esophageal fibrostenosis in EoE. (EoE). Low-level specific-IgE (sIgE) antibodies to CM are common in children with EoE and we recently reported that these children also have high-titer specific-IgG4 antibodies (sIgG4) to CM proteins. To better understand the relationship between sIgE and sIgG4 responses we sought to determine whether sIgE status was associated with sIgG4 titers to shared CM proteins, distinct CM proteins or an unrelated antigen (wheat). METHODS: In this sub-analysis of a recently reported cohort we included sera from 53 cases of pediatric EoE (mean age 11.4 [2-17yrs]; 35 boys/18 girls) who were consuming dairy. sIgG4 and sIgE were assayed with ImmunoCAP to major CM proteins (a-lactalbumin, b-lactoglobulin, caseins) and to CM and wheat extracts (cut-off > _0.1 IU/mL). RESULTS: Consistent with the parent cohort, sIgE titers to CM proteins were common (47-51%) but mostly low titer (ie.<3.5 IU/mL). Titers of sIgG4 to each CM protein were significantly higher in subjects who had detectable sIgE to the same antigen, but not to wheat. Within subjects that were sensitized to CM extract, there were significant differences in sIgG4 titer as a function of sIgE status to the same CM component protein.
Celgene Corporation, Summit, NJ. RATIONALE: The HEROES study evaluated RPC4046 in adults with active eosinophilic esophagitis (EoE). In this exploratory substudy, we investigated whether RPC4046 modulates epithelial-mesenchymal transition (EMT). METHODS: Esophageal biopsy sections were taken at baseline and week 16 from 69 patients receiving weekly subcutaneous RPC4046 360 mg (n526), 180 mg (n519), or placebo (n524). Slides were stained by duplex immunofluorescence for e-cadherin and vimentin, counterstained nuclei with DAPI, and scanned at 20x via multispectral digital microscopy. A machine-learning algorithm mapped each slide's epithelial compartment. Nuclear, cytoplasmic, and membrane areas of each epithelial cell were defined and fluorescence intensity of each marker on a per-cell basis was recorded. Endpoints included change from baseline in percentage of vimentin-positive epithelial cells, change in total e-cadherin expression/ cell, and change in vimentin:e-cadherin ratio/cell. RESULTS: Change from baseline in mean percentage of vimentinpositive cells was 24.24%, 22.75%, and 20.94% for RPC4046 360 mg, 180 mg, and placebo, respectively (P<0.05, 360 mg vs placebo). Change in mean e-cadherin expression per cell was 101.6, 102.4, and 18.3, respectively (P<0.05, each dose group vs placebo). Change in vimentin:e-cadherin ratio was significantly different from zero for 360 mg (20.30) and 180 mg (20.18) (P<0.05). Similar effects for all markers were observed in each esophageal sampled region. CONCLUSIONS: RPC4046 significantly improved esophageal tissue EMT markers in patients with EoE, with a greater effect observed with 360 mg. Results support the hypothesis that prevention of IL-13 binding to receptor subtypes IL-13Ra1 and IL-13Ra2 favorably impacts inflammatory and remodeling pathways and may reduce development of esophageal fibrostenosis in EoE. (EoE) . Low-level specific-IgE (sIgE) antibodies to CM are common in children with EoE and we recently reported that these children also have high-titer specific-IgG4 antibodies (sIgG4) to CM proteins. To better understand the relationship between sIgE and sIgG4 responses we sought to determine whether sIgE status was associated with sIgG4 titers to shared CM proteins, distinct CM proteins or an unrelated antigen (wheat). METHODS: In this sub-analysis of a recently reported cohort we included sera from 53 cases of pediatric EoE (mean age 11.4 [2-17yrs]; 35 boys/18 girls) who were consuming dairy. sIgG4 and sIgE were assayed with ImmunoCAP to major CM proteins (a-lactalbumin, b-lactoglobulin, caseins) and to CM and wheat extracts (cut-off > _0.1 IU/mL). RESULTS: Consistent with the parent cohort, sIgE titers to CM proteins were common (47-51%) but mostly low titer (ie.<3.5 IU/mL). Titers of sIgG4 to each CM protein were significantly higher in subjects who had detectable sIgE to the same antigen, but not to wheat. Within subjects that were sensitized to CM extract, there were significant differences in sIgG4 titer as a function of sIgE status to the same CM component protein.
CONCLUSIONS: Specific IgG4 to CM proteins are common and hightiter in children with EoE and here we show that IgG4 levels were most pronounced in those with detectable levels of IgE to the same antigen. This supports the specificity, and the link between sIgE and sIgG4, in the immune response to a relevant food-antigen in EoE. (EoE) is an increasing, chronic inflammatory disease with variable symptoms, pathologic features, and treatment response. We analyzed whole blood gene expression profiles in pediatric EoE patients before treatment to identify molecular pathways associated with clinical phenotypes. METHODS: RNAwas extracted from whole blood of 41 EoE patients and 20 healthy controls, and cDNA was hybridized to Illumina beadchips to measure gene expression. Medical records and questionnaires were reviewed to obtain information about symptoms, results of esophagogastroduodenoscopies, and treatment response. RESULTS: At baseline, 383 transcripts were differentially expressed between controls and EoE patients. Training and test analysis of RNA expression suggested different groups of EoE patients. When EoE patients were clinically classified based on food impaction (FI) (n515) or no food impaction (no FI) (n526), FI patients were more likely to have esophageal rings (p50.022) and less likely to have histologic remission after treatment (p50.013). Separate two-group comparisons of gene expression organized by hierarchical clustering segregated FI and no FI patients accurately from healthy controls. Then we calculated the transcriptional score (molecular distance to health [MDTH] ) that measures the transcriptional perturbation compared with healthy controls. Only patients with no FI (p50.0062) and not those with FI (p50.11) were significantly different from controls. CONCLUSIONS: Peripheral blood transcriptional analysis represents a promising noninvasive means to assess activity of the immune/inflammatory response in children with EoE that can be correlated with clinical manifestations.
